Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate / nebivolol hydrochloride, the active ingredient in Nebkliq, is a calcium channel blocker / beta‑blocker combination presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Nebkliq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebkliq is an antihypertensive medication that acts on vascular smooth muscle and cardiac beta‑1 receptors to lower blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Nebkliq may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Flushing: warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Fatigue: general tiredness. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Heart block: impaired electrical conduction of the heart. - Angioedema: swelling of face, lips, tongue or throat. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: check regularly to avoid excessive lowering. - Cardiac assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders. - Concomitant drugs review: assess for additive hypotensive or bradycardic agents. - Hepatic impairment: use with caution; dose adjustment may be needed. - Renal impairment: monitor renal function and adjust dose if required. - Store at room temperature: keep in the original pack, protect from moisture.

Nebkliq can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of excessive blood pressure drop. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): additive cardiac effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug levels. - Diuretics: may enhance hypotensive effect. - Antidiabetic agents: blood glucose may be affected by blood pressure changes.